NEVVI Medicare utilization intelligence
or

← back

Provider profile

GANDHI, DARSHAN M.B.B.S.

Hematology-Oncology · NPI 1285844092 · DALLAS, TX

1
Groups
34
Codes · 2024
18,835
Disclosed services

GANDHI, DARSHAN is a Hematology-Oncology in DALLAS, TX, a member of 1 medical group, who billed 34 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider analytics (2024)

GANDHI, DARSHAN billed 31,018 disclosed services in CY2023 and 18,835 in CY2024.

This provider's disclosed Medicare payments across all codes were $ in CY2024.

The full figure is part of the market analytics platform — built, not launched yet. Notify me at launch →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J1756 Injection, iron sucrose, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1100 Injection, dexamethasone sodium phosphate, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
80053 Blood test, comprehensive group of blood chemicals
J1626 Injection, granisetron hydrochloride, 100 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
96375 Injection of additional new drug or substance into vein
96372 Injection of drug or substance under skin or into muscle
83521 Measurement of immunoglobulin light chains
96415 Administration of chemotherapy into vein, each additional hour
J3489 Injection, zoledronic acid, 1 mg
85055 Reticulated (young) platelet measurement
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
83615 Lactate dehydrogenase (enzyme) level
96417 Administration of additional new drug or substance into vein, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J1200 Injection, diphenhydramine hcl, up to 50 mg
82232 Beta-2 microglobulin (protein) level
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
82607 Cyanocobalamin (vitamin b-12) level

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.